APLN and gestational diabetes: Furthermore, multiple studies have demonstrated that modulating this pathway (e.g., via Apelin-13 activation or miR-22/372 inhibition) significantly improves glycolipid metabolism and insulin sensitivity in GDM, suggesting its therapeutic potential [43,44].